Links to other pages within Patient UK which are related to this topic:
Experience | Leaflets | Diagrams | Weblinks | News | Products | Other
Print options:   Other options:   Bookmark and Share

This is a PatientPlus article. PatientPlus articles are written for doctors and so the language can be technical, however some people find that they add depth to the patient information leaflets. You may find the abbreviations record helpful.

Pancreatic Exocrine Tumours

Post your experience

Pancreatic cancer is a much feared disease due to its notoriously late presentation, early metastases and poor survival rates.

The pancreas has dual exocrine and endocrine function. Most pancreatic malignancies are exocrine. 90% of these are ductal adenocarcinomas. The majority arise in the head, neck or uncinate process. 90% of periampullary malignancies arise from the pancreas and the remaining 10% from the distal common bile duct, the ampulla of Vater and the duodenum. This subgroup carry better prognoses as they present with obstructive jaundice at an earlier stage. Rarer tumours (including intraductal papillary mucinous tumours and mucinous cystic tumours) also have a better prognosis.1 Metastases occur most commonly to the liver, peritoneum and lungs.

Epidemiology

Incidence2

  • Exocrine pancreatic tumours are the 6th commonest cause of cancer deaths in the UK and approximately 7000 cases diagnosed per year.
  • Due to poor survival rates, incidence and mortality rates are similar at approximately 10 cases per 100,000 population.

Risk factors2,3

Increased risk associated with:

  • Age - rare <40years, median age at presentation is 70-75 years.
  • Smoking - in the past, there has been a male excess of pancreatic cancer but women now account for 57% of new cases in US probably reflecting historical changes in smoking patterns.4
  • Increased BMI - association shown in postmenopausal women, particularly with central obesity.5
  • Chronic and hereditary pancreatitis - chronic pancreatitis is associated with a 5-15 fold increase in risk and hereditary pancreatitis with a 50-70 fold increase.
  • Family history- in up to 10% patients, there is a family history (at least 2 other family members) of pancreatic cancer. Risk is also increased in other cancer syndromes including hereditary non-polyposis colorectal carcinoma, familial adenomatous polyposis (strongly associated with periampullary tumours), familial breast-ovarian cancer syndromes, Peutz-Jeghers syndrome and familial melanoma syndromes.6

Dietary factors including fat intake, coffee consumption and alcohol have not been proven to increase risk.

Genetics3

  • High frequency genetic changes associated with pancreatic adenocarcinoma include: mutations of k-ras oncogene, inactivation of p53, p16 and smad4/TGF-β tumour suppressor genes.
  • The underlying genetic defects for hereditary syndromes with a predisposition for pancreatic cancer are being identified and may offer targets for future diagnostic and therapeutic interventions.
  • All patients at increased risk of inherited pancreatic cancer should be referred to a specialist centre for clinical advice and genetic counselling with appropriate genetic testing.2
Presentation1,7

General points:

  • Early symptoms are often vague and non specific (frequently epigastric discomfort or dull back ache) and their significance is frequently overlooked.
  • Symptoms are generally related to mass effect rather than disruption of exocrine or endocrine activity and exact clinical features will depend on the size and location of the tumour as well as its metastases.
  • More than two thirds occur in the head of the pancreas and classically present with painless, progressive, obstructive jaundice.
  • Patients with tumours in the body and tail of the pancreas generally present with nonspecific pain and weight loss and are much less likely to cause obstructive signs and symptoms.

Symptoms:

  • Related to obstructive jaundice - dark urine, pale stools, pruritus
  • Pain - back (typically dull and worse when supine, eased by sitting forward) and epigastric
  • Vomiting
  • Weight loss
  • Anorexia

Signs:

Courvoisier's law states that in the presence of jaundice, a palpable gall bladder is unlikely to be due to gall stones. This is because gall stones result in a fibrotic gall bladder which will not distend in the presence of obstruction of the common bile duct. Courvoisier's sign is 83-90% specific but only 26-55% sensitive for malignant obstruction of the bile duct, so absence of the sign does not rule out malignancy.

Patients presenting with rapid weight loss, persistent back pain, ascites, an epigastric mass or enlarged supraclavicular node (Virchow's node) are likely to have advanced disease.

Differential diagnosis

The differential diagnosis of upper right-sided or epigastric abdominal pain is wide and can include:

Differential diagnosis of obstructive jaundice or extrahepatic cholestasis:

  • Bile duct strictures (benign or malignant)
  • Common duct stone
  • Cancer of the head of the pancreas
  • Tumour of the ampulla of Vater
  • Pancreatitis
  • Cancer of the gallbladder

Certain presentations require increased suspicion of possible underlying pancreatic cancer:

  • "Idiopathic" acute pancreatitis (i.e. not related to gallstones or alcohol) over 50 years.
  • Diabetes mellitus in non obese patients over 50 years without definite risk factors.

These patient groups should also be referred for further investigation to exclude pancreatic cancer.

Investigations

Blood tests

  1. FBC to identify anaemia.
  2. LFTs - will confirm jaundice (raised bilirubin, usually with predominantly raised ALP and γ-GT) and disproportionate elevation of transaminases may lead to suspicion of hepatocellular involvement.
  3. There are no specific tumour markers - elevated CA 19-9 is usual but has low sensitivity (50-75%) and specificity (83%) and normal levels do not exclude diagnosis, though it may be useful to help predict prognosis and recurrent disease post resection.7 Other candidate markers include β-hCG and CA 72-4.

Radiology2,8

All methods can miss small tumours.

  1. Ultrasound - a scan of the liver, bile duct and pancreas is usually the primary investigation. It can show tumour mass, dilated bile ducts, bulky lymph nodes as well as any liver metastases. Its sensitivity at detecting pancreatic cancer is reported as 76-85% - usually due to most pancreatic cancer being advanced at presentation, but overlying bowel gas or fat may hide part of the pancreas so that continuing symptoms post-ultrasound should prompt CT.
  2. Abdominal CT is the imaging method of choice where suspicion is high of pancreatic cancer or pancreatitis. Helical and multidetector CT improve rates of tumour detection.

Staging procedures8,9

These are usually undertaken to assess suitability for surgical resection. Tissue diagnosis is also important in establishing prognosis. Investigations include:

  1. Multiphase spiral or helical CT with intravenous contrast- uptake at different times can show the degree of invasion of arteries, veins and surrounding tissues and distant lymphatic spread.
  2. Dynamic contrast-enhanced MRI, including magnetic resonance cholangiopancreatography (MRCP) and occasionally magnetic resonance angiography (MRA), will accurately delineate tumour size, its relationship with the vascular system and metastatic spread in most cases.
  3. Endoscopic ultrasonography (EUS) through gastric or duodenal wall (gastroscopy), if available, can be used to assist fine needle aspiration (FNA) or guided biopsy and is the most sensitive method for detecting small tumours. It is limited in its ability to stage tumours and is not widely available in the UK.
  4. Endoscopic retrograde cholangiopancreatography (ERCP) visualises the common bile duct and pancreatic duct and cancer of the head of the pancreas tends to produce a characteristic malignant stricture of the lower end of the common bile duct. It also allows brushings to be taken for cytology, biopsies to be taken and stenting undertaken at the same time. It has fallen from favour as a primary diagnostic test as small early cancers and those situated in the uncinate process may be missed, offers little guidance as to tumour size or spread and it carries the risk of inducing pancreatitis. It does allow for the insertion of a stent in those with obstructive jaundice.
  5. Transperitoneal biopsy can be used in patients selected for palliative treatment but should be avoided if lesion is resectable due to concerns regarding tumour cell seeding.
Staging7
Stage TNM classification Clinical classification Stage distribution at diagnosis (%) 5-year survival rate (%)
0 TIS, N0, M0 Resectable 7.5 15.2
IA T1, N0, M0      
IB T2, N0, M0      
IIA T3, N0, M0      
IIB T3, N1*,M0 Locally advanced 29.3 6.3
III T4, any N, M0      
IV Any T, any N, M1 Metastatic 47.2 1.6
  • TIS=insitu carcinoma; T1=tumour limited to pancreas but <2cm; T2=tumour limited to pancreas but larger than 2cm; T3=tumour extends beyond the pancreas but not into coeliac axis or superior mesenteric artery; T4=tumour involves coeliac axis or superior mesenteric artery.
  • N0=no regional lymph node metastasis; N1=regional lymph node metastasis.
  • M0=no distant metastasis; M1=distant metastasis.

*Tumours with regional lymph node involvement are sometimes considered surgically resectable if nodes are within the resection area.

Histology

Primary solid non-endocrine epithelial tumours

  • Ductal adenocarcinoma (75-90%)
  • Adeno-squamous carcinoma
  • Acinar cell carcinoma
  • Giant cell carcinoma
  • Pancreatoblastoma

Primary cystic non-endocrine epithelial tumours

  • Serous cystic neoplasms
  • Mucinous cystic neoplasms
  • Intraductal papillary-mucinous neoplasms
  • Solid and cystic papillary neoplasms
  • Acinar cell cystadenocarcinoma

Most non-inflammatory pancreatic cysts are malignant or pre-malignant - the main differential diagnosis is a pancreatic pseudocyst. Patients with pancreatic cysts are at an increased risk of developing other cancers of the pancreas but also extrapancreatic cancer. Serous cystadenomas are nearly always benign, usually managed conservatively under radiological surveillance.3

Management2,3

When pancreatic cancer is suspected on the basis of clinical and radiological findings, patients should be referred to designated pancreatic cancer centres for further assessment and treatment. Teams of experienced gastroenterologists, interventional radiologists, surgeons, pathologists, oncologists and palliative care specialists optimise the identification and survival of patients where surgery is appropriate and the best care for the majority with unresectable disease.

Resectable disease

Surgical resection of the tumour and neighbouring lymph nodes offers the only chance of cure but only 10-15% tumours are suitable for resection due to tumour size and spread at diagnosis. These should be performed in specialised centres as there is evidence of lower mortality and morbidity where high volume of this type of surgery is undertaken.10 Methods include:

  • Proximal pancreaticoduodenectomy with antrectomy (Whipple's procedure)
    • This is the classic operation for a tumour in the head of the pancreas and removes the head of the pancreas, the gall bladder, the distal common bile duct, the duodenum and proximal jejunum, the regional lymph nodes and 40-50% stomach.
    • It is a major operation and patients must be physically fit to undertake such radical surgery.
    • Median post-operative survival is 11-20 months, between 1.4 and 24% survive to 5 years but 40-50% of these ultimately die of recurrence and only 8% of those operated on remain tumour free.
    • Markers for long-term survival are: well-differentiated tumour, small tumour (<3cm diameter), clear resection margins and no lymph node involvement.
  • Proximal pancreaticoduodenectomy with pylorus preservation (modified Whipple's)
    • Stomach, pylorus and first 3-4 cm of duodenum are left intact.
    • There is no evidence of superiority of Whipple's versus modified Whipple's in terms of efficacy and survival - but the modified Whipple's has tended to be the preferred option in the UK due to shorter operating time, reduced blood loss, hospital stay, mortality and morbidity and complication rates - though these assumptions have been challenged.11
  • Total pancreaticoduodenectomy and distal pancreatectomy

Extended radical resections increase morbidity without improving survival or quality of life and are not part of routine practice.3

Adjuvant treatment

Surgery plus systemic adjuvant chemotherapy

Now recommended following ESPAC-1 trial12 which showed chemotherapy to improve survival (21% vs 8% at 5 years). Regimens commonly use either fluorouracil (5-FU) or gemcitabine.

Adjuvant radiotherapy or chemoradiotherapy

Early studies failed to show any survival benefit (ESPAC-1)12 - and neoadjuvant therapy remains investigational in pancreatic cancer.

Unresectable disease

The majority of patients (85-90%) fall into this category having locally advanced or metastatic disease.

Chemotherapy2

  • Many patients have a very limited survival expectancy and do not wish to undergo anticancer therapy.
    Pancreatic ductal adenocarcinoma is very resistant to conventional chemotherapy. However, increased duration of survival with palliative chemotherapy has been demonstrated in some trials.
  • Single-agent chemotherapy with gemcitabine (nucleoside analogue, inhibiting DNA synthesis) in advanced and metastatic tumours achieved modest but significant improvements in survival and symptom relief. Symptom improvement was found in more patients with gemcitabine compared to 5-fluorouracil, the traditional agent.13
  • NICE guidelines suggest that gemcitabine be used as first line palliative chemotherapy in pancreatic cancer provided there is reasonable performance status.14
  • Combination gemcitabine chemotherapy appears to be better than gemcitabine, the best combinations may be with capecitabine or platinum-based agents.15

Future directions for clinical management9,13

  • Preoperative chemoradiation for resectable disease
  • Gemcitabine as radiation sensitiser - use of chemoradiation regimens
  • Gemcitabine as an adjuvant treatment
  • Evolving gemcitabine-based combination therapies
  • Targeted therapy at identified molecular targets. e.g. the use of growth-factor inhibitors and monoclonal antibodies16

Palliative measures2

  • Obstructive jaundice and pruritus - obstruction of the common bile duct can be relieved by surgical bypass (choledochojejunostomy) or biliary stenting. Stenting relieves itch and reverses jaundice in about 85% patients. Stents can be inserted during an ERCP or percutaneously in those with extensive disease or otherwise unsuitable for surgery. A polyethylene stent has an average patency of 3-4 months, potentially leading to recurrent jaundice in those who survive longer than this. Expanding metal stents have a functional life approximately twice this and should be used for patients with good performance status and a locally advanced primary tumour <3cm.3,17Stents do block - this does not necessarily mean terminal progression of the tumour, so patients with re-occurrence of jaundice should be referred back for re-assessment .
  • Pain control - pain occurs in over 50% and may be severe and difficult to manage. Where opiates fail to control pain or are contraindicated/poorly tolerated, early referral to specialist palliative team is important - alternative analgesia, ablation of the coeliac ganglia, or external beam radiotherapy may provide significant improvement.
  • Malabsorption and weight loss - quality of life and steatorrhoea can be improved by the use of pancreatin supplements, titrated to prevent diarrhoea.
  • Nausea and vomiting - develops in about 20% and is often due to slowed gastric emptying and improved by prokinetic agents such as metoclopramide or domperidone. If due to duodenal obstruction, it may require duodenal stenting or bypass.
  • Depression - stronger association with pancreatic cancer compared to other malignancies so a low threshold for intervention and treatment may be appropriate.
Complications
  • Obstructive jaundice
  • Duodenal obstruction (15-20%)
  • Deep vein thrombosis or pulmonary embolus
  • Intractable pain (due to parenchymal pressure secondary to ductal obstruction, neural infiltration, pancreatic inflammation and associated biliary stenosis)
Prognosis

The majority of ductal carcinomas present when they are locally advanced and palliative treatments alone are possible. Only 4% of patients present with potentially curative disease. Overall 1 year and 5 year survival rates are 12% and 3% respectively. Without active treatment, metastatic disease has a median survival of 3-5 months and locally advanced disease of 6-10 months.3

Prevention2
  • Reducing tobacco consumption is likely to reduce cases of pancreatic cancer.
  • Physical activity, high fruit and vegetable intake, avoiding central obesity may have a protective effect.
  • The use of nonsteroidal anti-inflammatory drugs18 may also have a protective effect - although this is unproven and investigational.
  • No simple screening test is currently available for use in the general population.
  • Secondary screening in high risk cases (chronic pancreatitis, hereditary pancreatitis, familial pancreatic cancer, ovarian and breast cancer familial syndrome and familial multiple mole melanoma syndrome) may be carried out as part of an investigational programme through specialist centres only.


Document references
  1. Bowles MJ, Benjamin IS; ABC of the upper gastrointestinal tract: Cancer of the stomach and pancreas.; BMJ. 2001 Dec 15;323(7326):1413-6.
  2. No authors listed; Guidelines for the management of patients with pancreatic cancer periampullary and ampullary carcinomas.; Gut. 2005 Jun;54 Suppl 5:v1-16.
  3. Ghaneh P, Costello E, Neoptolemos JP; Biology and management of pancreatic cancer. Gut. 2007 Aug;56(8):1134-52.
  4. Doll R, Peto R, Wheatley K, et al; Mortality in relation to smoking: 40 years' observations on male British doctors.; BMJ. 1994 Oct 8;309(6959):901-11. [abstract]
  5. Luo J, Margolis KL, Adami HO, et al; Obesity and risk of pancreatic cancer among postmenopausal women: the Women's Health Initiative (United States). Br J Cancer. 2008 Aug 5;99(3):527-31. Epub 2008 Jul 15. [abstract]
  6. Hansson J; Familial melanoma. Surg Clin North Am. 2008 Aug;88(4):897-916. [abstract]
  7. Freelove R, Walling AD; Pancreatic cancer: diagnosis and management.; Am Fam Physician. 2006 Feb 1;73(3):485-92. [abstract]
  8. Guthrie JA, Sheridan MB; Investigation of abdominal pain to detect pancreatic cancer. BMJ. 2008 May 10;336(7652):1067-9.
  9. Yang GY, Wagner TD, Fuss M, et al; Multimodality approaches for pancreatic cancer.; CA Cancer J Clin. 2005 Nov-Dec;55(6):352-67. [abstract]
  10. Topal B, Van de Sande S, Fieuws S, et al; Effect of centralization of pancreaticoduodenectomy on nationwide hospital mortality and length of stay. Br J Surg. 2007 Nov;94(11):1377-81. [abstract]
  11. Tran KT, Smeenk HG, van Eijck CH, et al; Pylorus preserving pancreaticoduodenectomy versus standard Whipple procedure: a prospective, randomized, multicenter analysis of 170 patients with pancreatic and periampullary tumors.; Ann Surg. 2004 Nov;240(5):738-45. [abstract]
  12. Neoptolemos JP, Stocken DD, Friess H, et al; A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer.; N Engl J Med. 2004 Mar 18;350(12):1200-10. [abstract]
  13. Li D, Xie K, Wolff R, et al; Pancreatic cancer.; Lancet. 2004 Mar 27;363(9414):1049-57. [abstract]
  14. Pancreatic cancer - gemcitabine, NICE Technology Appraisal (2001); The use of gemcitabine for the treatment of pancreatic cancer.
  15. Sultana A, Tudur Smith C, Cunningham D, et al; Meta-analyses of chemotherapy for locally advanced and metastatic pancreatic cancer: results of secondary end points analyses. Br J Cancer. 2008 Jul 8;99(1):6-13. Epub 2008 Jun 24. [abstract]
  16. Cardenes HR, Chiorean EG, Dewitt J, et al; Locally advanced pancreatic cancer: current therapeutic approach. Oncologist. 2006 Jun;11(6):612-23. [abstract]
  17. Moss AC, Morris E, Mac Mathuna P; Palliative biliary stents for obstructing pancreatic carcinoma.; Cochrane Database Syst Rev. 2006 Apr 19;(2):CD004200. [abstract]
  18. Sarkar FH, Adsule S, Li Y, et al; Back to the future: COX-2 inhibitors for chemoprevention and cancer therapy. Mini Rev Med Chem. 2007 Jun;7(6):599-608. [abstract]

Internet and further reading Acknowledgements EMIS is grateful to Dr Chloe Borton for writing this article. The final copy has passed scrutiny by the independent Mentor GP reviewing team. ©EMIS 2009.
Document ID: 1326
Document Version: 22
Document Reference: bgp899
Last Updated: 21 Sep 2008
Planned Review: 21 Sep 2010

The authors and editors of this article are employed to create accurate and up to date content reflecting reliable research evidence, guidance and best clinical practice. They are free from any commercial conflicts of interest. Find out more about updating.

Links to other pages within Patient UK which are related to this topic:
Experience | Leaflets | Diagrams | Weblinks | News | Products | Other
Print options:   Other options:   Bookmark and Share
Want to search some more? Use the Google Search box below to search our site.

Related pages in Patient UK

Your Experience (^ top of page)

 Please add your experience about this condition / medicine
 Pancreas
 Pancreatitis - Acute
 Pancreatitis - Chronic

 Pancreas (diagram)

 Pancreatitis

Latest Health News

 View current health news

Medical equipment


Visit the Patient UK Medical Equipment shop

Books


Visit the Patient UK shop

Other - Useful resources (^ top of page)

Pictures, diagrams, photos, images, etc.
Evidence based medicine
Online textbooks and journals
UK Guidelines
Online Videos
Medline
Other good health sites

Want to search some more? Use the Google Search box below to search our site.

Advertisements













Disclaimer: Patient UK has no control over the content of any external links above. Inclusion does not imply endorsement by Patient UK.

Want to advertise on this site? Find out how >>

Clicking here will take you to the foot of this page where you'll find a list of Information Leaflets which are related to the topic you are currently viewing
Clicking here will take you to the foot of this page where you'll find a list of Support Groups which are related to the topic you are currently viewing
Clicking here will take you to the foot of this page where you'll find a list of Medicines & Drugs which are related to the topic you are currently viewing
Clicking here will take you to the foot of this page where you'll find a list of diagrams which are related to the topic you are currently viewing
Clicking here will take you to the foot of this page where you'll find a list of PatientPlus (detailed reference) articles which are related to the topic you are currently viewing
Clicking here will take you to the foot of this page where you'll find a list of UK Guidelines which are related to the topic you are currently viewing
Clicking here will take you to the foot of this page where you'll find a list of other selected websites which are related to the topic you are currently viewing
Clicking here will take you to the foot of this page where you'll find a list of Poems and Stories which are related to the topic you are currently viewing
Clicking here will take you to the foot of this page where you'll find a list of Operations and Procedures which are related to the topic you are currently viewing
Clicking here will take you to the foot of this page where you'll find a list of Online Videos which are related to the topic you are currently viewing
Clicking here will take you to the foot of this page where you'll find links through to our interactive forum.
Here you can follow a link to view existing patient experiences on this subject, or to add your own
Clicking here will take you to the foot of this page where you'll find links to news stories on this subject in our Online Newspaper
Clicking here will take you to the foot of this page where you'll find links to related products
Clicking here will take you to the foot of this page where you'll find links to other useful sources of information
Click here to open a printer-friendly version of this document, in a new window, together with the print dialogue box
Click here to open this document in PDF format
This will offer you the usual PDF options i.e. document navigation, search, zoom and formatted print
Note: this is the best way to print the document
Click here to listen to the MP3 audio recording of this document
Click here to download the audio recording of this document as a podcast, for listening to at your leisure
Click here to open our Dictionaries and Glossaries page
Click here to see related products in our Online Pharmacy
Note: this will open in a new window
Click here to add this page to a social bookmarking site of your choice
Click here if you want to find out more about social bookmarking. This link will take you to the Wikipedia explanation
Note: this will open in a new window
Clicking here will take you to the foot of this page where you'll find a list of Information Leaflets which are related to the topic you are currently viewing
Clicking here will take you to the foot of this page where you'll find a list of Support Groups which are related to the topic you are currently viewing
Clicking here will take you to the foot of this page where you'll find a list of Medicines & Drugs which are related to the topic you are currently viewing
Clicking here will take you to the foot of this page where you'll find a list of diagrams which are related to the topic you are currently viewing
Clicking here will take you to the foot of this page where you'll find a list of PatientPlus (detailed reference) articles which are related to the topic you are currently viewing
Clicking here will take you to the foot of this page where you'll find a list of UK Guidelines which are related to the topic you are currently viewing
Clicking here will take you to the foot of this page where you'll find a list of other selected websites which are related to the topic you are currently viewing
Clicking here will take you to the foot of this page where you'll find a list of Poems and Stories which are related to the topic you are currently viewing
Clicking here will take you to the foot of this page where you'll find a list of Operations and Procedures which are related to the topic you are currently viewing
Clicking here will take you to the foot of this page where you'll find a list of Online Videos which are related to the topic you are currently viewing
Clicking here will take you to the foot of this page where you'll find links through to our interactive forum.
Here you can follow a link to view existing patient experiences on this subject, or to add your own
Clicking here will take you to the foot of this page where you'll find links to news stories on this subject in our Online Newspaper
Clicking here will take you to the foot of this page where you'll find links to related products
Clicking here will take you to the foot of this page where you'll find links to other useful sources of information
Click here to open a printer-friendly version of this document, in a new window, together with the print dialogue box
Click here to open this document in PDF format
This will offer you the usual PDF options i.e. document navigation, search, zoom and formatted print
Note: this is the best way to print the document
Click here to listen to the MP3 audio recording of this document
Click here to download the audio recording of this document as a podcast, for listening to at your leisure
Click here to open our Dictionaries and Glossaries page
Click here to see related products in our Online Pharmacy
Note: this will open in a new window
Click here to add this page to a social bookmarking site of your choice
Click here if you want to find out more about social bookmarking. This link will take you to the Wikipedia explanation
Note: this will open in a new window